

Alcohol Craving - Moderate Imputation

Author(s) and Year	Medication	Dose		DpM	BrAC	Hedge's G [95% CI]
Brasser et al., 2004	Acamprosate	4000		112.4	0.11	0.08 [-0.72, 0.87]
Hammarberg et al., 2009	Acamprosate	1998		174.1	0.055	-0.11 [-0.70, 0.49]
Voronin et al., 2008	Aripiprazole	15		211.7	0.022	0.04 [-0.66, 0.74]
Evans & Bisaga, 2009	Baclofen	80		120.9	0.09	-0.16 [-0.78, 0.46]
Pierucci-Lagha et al., 2005	Finasteride	100		11.1	0.06	-0.26 [-0.91, 0.40]
Bisaga & Evans, 2006	Gabapentin	2000		147	0.09	-0.32 [-1.10, 0.46]
Myrick et al., 2007	Gabapentin	1200		177.8	0.021	-0.46 [-1.12, 0.20]
Ray et al., NA	lbutilast	100		138.8	0.08	-0.05 [-0.32, 0.22]
Pickworth et al., 1997	Indomethacin	58.74		51.4	0.115	-0.40 [-1.54, 0.73]
Roche et al., 2016	Ivermectin	30		168.3	0.08	-0.22 [-0.65, 0.22]
Blomqvist et al., 2002	Mecamylamine	12.5		15	0.071	-0.40 [-0.74, -0.06]
Chi and de Wit, 2003	Mecamylamine	15		32.4	0.08	-0.26 [-0.99, 0.48]
Young et al., 2005	Mecamylamine	15		36.4	0.02	-0.27 [-0.96, 0.42]
Bisaga & Evans, 2003	Memantine	30		87.9	0.1	-0.59 [-0.99, -0.20]
Krishnan-Sarin et al., 2015	Memantine	40		165.5	0.03	-0.37 [-0.78, 0.04]
Drobes et al., 2004	Nalmefene	50		186.8	0.055	-0.50 [-0.95, -0.04]
Drobes et al., 2004	Nalmefene	50		17.8	0.055	-0.63 [-1.16, -0.09]
Anton et al., 2004	Naltrexone	50		160	0.03	-0.21 [-0.82, 0.40]
Anton et al., 2012	Naltrexone	50		174.9	0.025	-0.23 [-0.67, 0.21]
Bujarski et al., 2012	Naltrexone	50		48.1	0.06	-0.22 [-0.45, 0.00]
Drobes et al., 2004	Naltrexone	50		186.8	0.055	-0.23 [-0.66, 0.19]
Drobes et al., 2004	Naltrexone	50		17.8	0.055	-0.43 [-0.95, 0.08]
McCaul et al., 2000	Naltrexone	100		55.2	0.088	-0.48 [-0.98, 0.02]
Na and Lee, 2002	Naltrexone	50		19	0.074	-0.73 [-1.26, -0.21]
O'Malley et al., 2002	Naltrexone	50		142.7	0.03	-0.80 [-1.78, 0.17]
Ray et al., 2012	Naltrexone	50		48.4	0.06	-0.13 [-0.41, 0.14]
Ray et al., 2014	Naltrexone	25		135.4	0.067	0.03 [-0.47, 0.53]
Ray et al., 2007	Naltrexone	50		44	0.06	-0.37 [-0.60, -0.14]
Ray et al., 2008	Naltrexone	50		41.7	0.033	-0.48 [-0.76, -0.21]
Ray et al., 2007	Naltrexone	50		43.7	0.06	-0.06 [-0.58, 0.46]
Setiawan et al., 2011	Naltrexone	50		66.4	0.01	-0.07 [-0.28, 0.14]
Spagnolo et al., 2014	Naltrexone	50		336.6	0.08	-0.17 [-0.61, 0.27]
Doty et al., 1997	Naltrexone	50		39	0.025	-0.27 [-0.95, 0.42]
de Wit et al., 1999	Naltrexone	50		34.3	0.09	-0.06 [-0.56, 0.44]
Hutchison et al., 2001	Olanzapine	5		100.9	0.06	-0.26 [-1.01, 0.49]
Hutchison et al., 2003	Olanzapine	5		43.5	0.06	-0.66 [-1.15, -0.17]
Ray et al., 2011	Quetiapine	400		138.9	0.06	-0.37 [-1.35, 0.61]
George et al., 2010	Rimonabant	20		153.3	0.03	-0.21 [-0.83, 0.40]
Miranda et al., 2008	Topiramate	300		122.4	0.08	-0.12 [-0.62, 0.38]
Childs et al., 2012	Varenicline	2		69.4	0.09	-0.57 [-1.00, -0.14]
McKee et al., 2009	Varenicline	2		128.3	0.021	-0.75 [-1.53, 0.03]
Ray et al., 2014	Varenicline	2		135.4	0.067	0.23 [-0.28, 0.73]
Sarid-Segal et al., 2009	Zonisamide	100		102	0.03	-0.40 [-1.42, 0.61]

